To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).
Pharmaceutical Technology on MSN22h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHLilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback